Subject of the article

Authors

Berdiyarova Sh.Sh., Najmiddinova N.K., Abdumannonova M.O.

Institution

Samarkand State Medical University. Samarkand, Uzbekistan

Abstract

Bronchial asthma is currently a common disease among respiratory diseases, leading to se vere complications. This disease is a chronic inflammatory disease of the airways, characterized by recur rent obstruction, hyperreactivity and inflammation. The main symptoms are wheezing, cough, shortness of breath and a feeling of tightness in the chest, which vary in intensity and frequency. This article analyzes the methods of rehabilitation of patients with this disease. Bronchial asthma is a chronic inflammatory disease, in the pathogenesis of which interleukins play an important role. At the rehabilitation stage, these cytokines are of great importance not only for assessing the activity of the disease, but also for monitoring the patient's condition, determining the effectiveness of treatment and developing an individual approach. This article highlights the immunological and clinical role of interleukins (especially IL-4, IL-5, IL-13 and IL-17) in the rehabilitation process.

Key words

bronchial asthma, cough, dyspnea, rehabilitation, obstruction, eosinophil, relapse.

Literature

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Pre vention, 2024.
2. Barnes PJ. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine & Growth Factor Reviews, 2018; 39: 62–73.
3. Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nature Reviews Immunology, 2015; 15(1): 57–65.
4. Чучалин А.Г. Бронхиальная астма: Руко водство для врачей. — М.: ГЭОТАР-Медиа, 2020. — 528 с.
5. Иванова Л.А., Ермакова Т.И. Современ ные подходы к реабилитации больных бронхи альной астмой // Пульмонология. — 2019. — №3. — С. 34–39.
6. Киселев В.В. Терапевтический потенци ал антицитокиновой терапии в пульмонологии // Вестник современной клинической медицины. — 2021. — №2. — С. 11–16.
7. Международные рекомендации GINA (Global Initiative for Asthma) по ведению и лече нию бронхиальной астмы. Перевод и адаптация — 2023 г.
8. Kuperman D, Schleimer RP. Interleukin-13 in asthma pathogenesis. Current Allergy and Asthma Reports, 2008; 8(5): 371–375.
9. Corren J et al. Lebrikizumab treatment in adults with asthma. New England Journal of Medi cine, 2011; 365(12): 1088–1098.
10. Al-Ramli W et al. TH17-associated cyto kines (IL-17A and IL-17F) in severe asthma. Journal of Allergy and Clinical Immunology, 2009; 123(5): 1185–1187.
11. Agache I et al. EAACI position paper on the use of biologics in severe asthma. Allergy, 2020; 75(1): 14–23.
12. Wenzel SE. Asthma phenotypes: the evo lution from clinical to molecular approaches. Nature Medicine, 2012; 18(5): 716–725.
13. Алексеев А.А. Биомаркеры воспаления в оценке эффективности реабилитации при бронхиальной астме // Клиническая медицина. — 2020. — Т. 98, №6. — С. 437–442.